Verrica Pharmaceuticals (NASDAQ:VRCA) PT Lowered to $10.00 at TD Cowen

Verrica Pharmaceuticals (NASDAQ:VRCA) had its price objective trimmed by TD Cowen from $15.00 to $10.00 in a research report released on Monday morning, Benzinga reports. The firm currently has a buy rating on the stock.

Other research analysts also recently issued reports about the company. Royal Bank of Canada cut their price target on Verrica Pharmaceuticals from $13.00 to $11.00 and set an “outperform” rating for the company in a report on Friday, October 4th. Brookline Capital Management reaffirmed a “hold” rating on shares of Verrica Pharmaceuticals in a research report on Wednesday, October 2nd. Finally, Needham & Company LLC reiterated a “hold” rating and set a $12.00 target price on shares of Verrica Pharmaceuticals in a research report on Thursday, October 3rd. Two research analysts have rated the stock with a hold rating and four have issued a buy rating to the company’s stock. According to MarketBeat, the stock has an average rating of “Moderate Buy” and a consensus target price of $11.40.

Verrica Pharmaceuticals Trading Down 5.0 %

Verrica Pharmaceuticals stock opened at $1.51 on Monday. The stock has a 50-day moving average price of $1.92 and a 200 day moving average price of $5.53. Verrica Pharmaceuticals has a 52 week low of $1.04 and a 52 week high of $11.41. The stock has a market cap of $64.05 million, a PE ratio of -0.86 and a beta of 1.45. The company has a current ratio of 2.36, a quick ratio of 2.23 and a debt-to-equity ratio of 29.58.

Verrica Pharmaceuticals (NASDAQ:VRCA) last issued its quarterly earnings results on Wednesday, August 14th. The company reported ($0.37) EPS for the quarter, topping analysts’ consensus estimates of ($0.43) by $0.06. The business had revenue of $5.18 million during the quarter, compared to the consensus estimate of $4.70 million. Verrica Pharmaceuticals had a negative net margin of 625.06% and a negative return on equity of 591.84%. Equities research analysts predict that Verrica Pharmaceuticals will post -1.58 earnings per share for the current fiscal year.

Institutional Trading of Verrica Pharmaceuticals

Institutional investors have recently made changes to their positions in the stock. Simplify Asset Management Inc. acquired a new position in Verrica Pharmaceuticals in the second quarter valued at $2,041,000. Renaissance Technologies LLC purchased a new position in shares of Verrica Pharmaceuticals in the 2nd quarter worth about $332,000. Key Financial Inc acquired a new position in shares of Verrica Pharmaceuticals in the 2nd quarter valued at about $69,000. Vanguard Group Inc. grew its holdings in shares of Verrica Pharmaceuticals by 0.6% during the 1st quarter. Vanguard Group Inc. now owns 1,268,710 shares of the company’s stock worth $7,511,000 after purchasing an additional 7,609 shares during the period. Finally, Quest Partners LLC acquired a new stake in Verrica Pharmaceuticals during the 2nd quarter worth approximately $50,000. 42.45% of the stock is owned by hedge funds and other institutional investors.

Verrica Pharmaceuticals Company Profile

Verrica Pharmaceuticals Inc, a clinical-stage dermatology therapeutics company, develops medications for the treatment of skin diseases in the United States. Its product pipeline comprises YCANTH (VP-102), which is in phase III clinical trial for the treatment of common warts; and has completed phase II clinical trial for the treatment of external genital warts.